| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
L2H2-6OTD intermediate-2 is a chemical building block and does not have a direct pharmacological target. The final telomerase inhibitors synthesized from this intermediate target telomerase, an enzyme that maintains telomere length and is implicated in cancer cell immortality. Telomerase is a ribonucleoprotein that adds telomeric repeats to chromosome ends, and its inhibition is a promising strategy for cancer therapy.
|
|---|---|
| ln Vitro |
As a synthetic intermediate, L2H2-6OTD intermediate-2 itself does not exhibit biological activity. Its utility lies in its use as a building block for the synthesis of telomerase inhibitors and ADCs. The compound is not evaluated for traditional in vitro activity such as IC50 values against cell lines.
|
| ln Vivo |
L2H2-6OTD intermediate-2 is not a therapeutic compound and is not evaluated for in vivo activity in the traditional sense. Its primary application is as a synthetic intermediate in the preparation of telomerase inhibitors and ADCs for research purposes.
|
| Enzyme Assay |
Non-cell-based protocols for L2H2-6OTD intermediate-2 involve chemical synthesis and characterization of the compound and its derivatives. A typical protocol includes dissolving the intermediate in an appropriate solvent, performing chemical reactions to couple it with other building blocks, and purifying the product by chromatography. The compound is characterized by NMR, HPLC, and mass spectrometry to confirm its structure and purity.
|
| Cell Assay |
Cellular assays are not applicable to L2H2-6OTD intermediate-2 as it is a synthetic intermediate. The final telomerase inhibitors or ADCs synthesized from this intermediate would be evaluated in cell-based assays for their biological activity.
|
| Animal Protocol |
In vivo animal studies are not applicable to L2H2-6OTD intermediate-2 as it is a synthetic intermediate. The final telomerase inhibitors or ADCs synthesized from this intermediate would be evaluated in animal models for their efficacy and safety.
|
| ADME/Pharmacokinetics |
L2H2-6OTD intermediate-2 is a synthetic intermediate and is not evaluated for pharmacokinetic properties as a drug. The compound is stored at 4°C under nitrogen, away from moisture.
|
| Toxicity/Toxicokinetics |
As a synthetic intermediate for research use, L2H2-6OTD intermediate-2 is not intended for human therapeutic use, and comprehensive toxicological data are not available. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
L2H2-6OTD intermediate-2 (CAS 890403-75-5) is a synthetic intermediate of telomerase inhibitors that can be used in the synthesis of antibody-drug conjugates (ADCs). It has a molecular formula of C14H20N2O6 and a molecular weight of 312.32 g/mol. As a synthetic building block, L2H2-6OTD intermediate-2 is used in the preparation of more complex molecules for research applications in oncology and drug development.
|
| Molecular Formula |
C14H20N2O6
|
|---|---|
| Molecular Weight |
312.318404197693
|
| Exact Mass |
312.132
|
| CAS # |
890403-75-5
|
| PubChem CID |
11954900
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
459
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1(N([C@@H](CO1)C2=NC(=CO2)C(=O)O)C(=O)OC(C)(C)C)C
|
| InChi Key |
ROGULVVSLYGJPQ-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C14H20N2O6/c1-13(2,3)22-12(19)16-9(7-21-14(16,4)5)10-15-8(6-20-10)11(17)18/h6,9H,7H2,1-5H3,(H,17,18)/t9-/m0/s1
|
| Chemical Name |
2-[(4S)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-oxazolidin-4-yl]-1,3-oxazole-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2018 mL | 16.0092 mL | 32.0184 mL | |
| 5 mM | 0.6404 mL | 3.2018 mL | 6.4037 mL | |
| 10 mM | 0.3202 mL | 1.6009 mL | 3.2018 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
